Market Place
Sourcing Support
NRG Therapeutics Selects NRG5051, Receives Michael Foundation Grant
31 Oct 2024 //
GLOBENEWSWIRE
NRG Therapeutics Awarded Grant From Target ALS
05 Sep 2024 //
GLOBENEWSWIRE
NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair
26 Apr 2023 //
GLOBENEWSWIRE
NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology
19 Apr 2023 //
GLOBENEWSWIRE
NRG Therapeutics Announces International Scientific Advisory Board
30 Mar 2023 //
GLOBENEWSWIRE
NRG Awarded Second $500K Grant from The Michael J. Fox Foundation
22 Feb 2023 //
GLOBENEWSWIRE
NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry
09 Feb 2023 //
GLOBENEWSWIRE
NRG Therapeutics Announces £16 million Series A to Advance Mitochondrial
09 Nov 2022 //
PRNEWSWIRE
NRG announces £16m Series A for IND for Parkinson’s and ALS
09 Nov 2022 //
PHARMAPHORUM
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.